株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非アルコール性脂肪肝疾患(NAFLD): パイプライン分析

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 251566
出版日 ページ情報 英文 176 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.48円で換算しております。
Back to Top
非アルコール性脂肪肝疾患(NAFLD): パイプライン分析 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017
出版日: 2017年02月28日 ページ情報: 英文 176 Pages
概要

非アルコール性脂肪肝疾患は、慢性肝疾患の最も一般的な原因の1つです。この疾患は、よく見られる病気で、ほとんどの人は症侯や合併症が見られませんが、人によっては蓄積された脂肪のせいで肝臓に炎症や傷を引き起こすことがあります。 最も顕著な症状としては、倦怠感、疲労感、腹部の右上四分の一か全体に広がる不快感があります。

当レポートでは、非アルコール性脂肪肝疾患(NAFLD)の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

非アルコール性脂肪肝疾患(NAFLD) 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Arisaph Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Betagenon AB
  • Can-Fite BioPharma Ltd.
  • Conatus Pharmaceuticals Inc.
  • Corcept Therapeutics Incorporated
  • Daewoong Pharmaceutical Co., Ltd.
  • Dimerix Bioscience Pty Ltd
  • Dr. Falk Pharma GmbH
  • DURECT Corporation
  • Galmed Pharmaceuticals Ltd.
  • Gilead Sciences, Inc.
  • Huons Co., Ltd.
  • キョーリン製薬
  • Novartis AG
  • Sancilio & Company, Inc.
  • TaiwanJ Pharmaceuticals Co., Ltd.
  • TCM Biotech International Corp
  • Tobira Therapeutics, Inc.
  • Verva Pharmaceuticals Limited
  • Zafgen Inc.
  • Zydus Cadila Healthcare Limited

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (ロイシン + 塩酸メトホルミン + クエン酸シルデナフィル)
  • (ロイシン + PDE5 阻害剤)
  • Aramchol
  • ARI-3037MO
  • C-10
  • cenicriviroc mesylate
  • CF-102
  • CORT-118335
  • DMX-300
  • 消化器疾患・代謝障害治療用 ABHD6阻害薬
  • DUR-928
  • DWP-10292
  • emricasan
  • FLB-12
  • GS-9674
  • HU-002
  • KDT-501
  • MAT-8800
  • methazolamide
  • MN-002
  • 塩酸ナルトレキソン
  • norursodeoxycholic acid
  • O-304
  • oltipraz
  • pradigastat sodium
  • Px-103
  • saroglitazar
  • SC-410
  • 非アルコール性脂肪性肝炎・非アルコール性脂肪肝疾患治療薬
  • 脂肪肝疾患治療用AMPK活性薬
  • 代謝障害治療用 NaCT阻害剤
  • TCM-606F
  • VVP-100-X
  • ZGN-839

最近のパイプライン動向

休止中のプロジェクト

)■開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8972IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 15, 8, 2, 16 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 5
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Overview 8
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Development 9
  • Pipeline Overview 9
  • Pipeline by Companies 10
  • Pipeline by Universities/Institutes 14
  • Products under Development by Companies 15
  • Products under Development by Universities/Institutes 18
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment 19
  • Assessment by Target 19
  • Assessment by Mechanism of Action 22
  • Assessment by Route of Administration 25
  • Assessment by Molecule Type 27
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development 29
  • Allergan Plc 29
  • Arisaph Pharmaceuticals Inc 29
  • AstraZeneca Plc 30
  • Betagenon AB 30
  • Bird Rock Bio Inc 31
  • Can-Fite BioPharma Ltd 31
  • Cerenis Therapeutics Holding SA 32
  • Conatus Pharmaceuticals Inc 32
  • Corcept Therapeutics Inc 33
  • CymaBay Therapeutics Inc 33
  • Daewoong Pharmaceutical Co Ltd 34
  • Dimerix Bioscience Pty Ltd 34
  • Dr. Falk Pharma GmbH 35
  • DURECT Corp 35
  • Enanta Pharmaceuticals Inc 36
  • Eternygen GmbH 36
  • Galmed Pharmaceuticals Ltd 37
  • Gemphire Therapeutics Inc 37
  • Genfit SA 38
  • Gilead Sciences Inc 38
  • Huons Co Ltd 39
  • Immuron Ltd 39
  • Kyorin Pharmaceutical Co Ltd 40
  • Matinas BioPharma Holdings Inc 40
  • Miyarisan Pharmaceutical Company Ltd 41
  • NovaTarg Therapeutics Inc 41
  • Pfizer Inc 42
  • Renova Therapeutics Inc 42
  • Sancilio & Company Inc 43
  • TaiwanJ Pharmaceuticals Co Ltd 43
  • TCM Biotech International Corp 44
  • Zydus Cadila Healthcare Ltd 44
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Drug Profiles 45
  • (leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile 45
  • (leucine + PDE5 Inhibitor) - Drug Profile 47
  • AC-261066 - Drug Profile 48
  • Aramchol - Drug Profile 49
  • ARI-3037MO - Drug Profile 55
  • AZD-4076 - Drug Profile 57
  • C-10 - Drug Profile 59
  • CBM-588 - Drug Profile 61
  • cenicriviroc mesylate - Drug Profile 63
  • CER-209 - Drug Profile 71
  • CORT-118335 - Drug Profile 72
  • dapagliflozin propanediol - Drug Profile 73
  • DMX-300 - Drug Profile 80
  • Drug to Antagonize MCJ for Gastrointestinal Disorders - Drug Profile 81
  • DUR-928 - Drug Profile 82
  • DWP-10292 - Drug Profile 86
  • EDP-305 - Drug Profile 87
  • elafibranor - Drug Profile 88
  • emricasan - Drug Profile 96
  • FLB-12 - Drug Profile 104
  • gemcabene calcium - Drug Profile 105
  • GS-0976 - Drug Profile 109
  • GS-9674 - Drug Profile 111
  • HTD-1801 - Drug Profile 114
  • HU-002 - Drug Profile 115
  • IMM-124E - Drug Profile 116
  • liothyronine sodium - Drug Profile 119
  • MAT-8800 - Drug Profile 120
  • MN-002 - Drug Profile 121
  • naltrexone hydrochloride - Drug Profile 123
  • Namacizumab - Drug Profile 125
  • namodenoson - Drug Profile 126
  • NLM-0100 - Drug Profile 131
  • norursodeoxycholic acid - Drug Profile 132
  • O-304 - Drug Profile 134
  • oltipraz - Drug Profile 136
  • PF-06835919 - Drug Profile 137
  • RT-200 - Drug Profile 138
  • RT-210 - Drug Profile 139
  • saroglitazar - Drug Profile 140
  • SC-410 - Drug Profile 142
  • seladelpar - Drug Profile 143
  • selonsertib - Drug Profile 147
  • Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile 149
  • Small Molecules for Non-Alcoholic Steatohepatitis and Non Alcoholic Fatty Liver Disease - Drug Profile 150
  • Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 151
  • Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile 152
  • Synthetic Peptides for Non Alcoholic Fatty Liver Disease and Non Alcoholic Steatohepatitis - Drug Profile 153
  • TCM-606F - Drug Profile 154
  • tipelukast - Drug Profile 155
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects 160
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products 161
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones 162
  • Featured News & Press Releases 162
  • Appendix 172
  • Methodology 172
  • Coverage 172
  • Secondary Research 172
  • Primary Research 172
  • Expert Panel Validation 172
  • Contact Us 172
  • Disclaimer 173

List of Tables

  • Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Allergan Plc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Bird Rock Bio Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cerenis Therapeutics Holding SA, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Conatus Pharmaceuticals Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by CymaBay Therapeutics Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dimerix Bioscience Pty Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corp, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Enanta Pharmaceuticals Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eternygen GmbH, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gemphire Therapeutics Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Genfit SA, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gilead Sciences Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Co Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Immuron Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NovaTarg Therapeutics Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Pfizer Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Renova Therapeutics Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sancilio & Company Inc, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H1 2017
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top